![]() |
市場調查報告書
商品編碼
1496762
臨床試驗用品市場:按階段、類型、產品、治療領域和最終用戶分類 - 全球預測 2024-2030Clinical Trial Supplies Market by Phase (Phase I, Phase II, Phase III), Type (Biologic Drugs, Medical Devices, Small-Molecules), Product, Therapeutic Area, End User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年臨床試驗用品市場規模為33.5億美元,2024年達36.4億美元,預計2030年將達到59.2億美元,複合年成長率為8.43%。
研究是臨床研究的一個基本而複雜的要素,最終有助於為成功的治療方法突破和患者治療途徑的突破性改進鋪平道路。這些用品支持從臨床前測試到上市後監測的各個研究階段,促進臨床試驗的無縫管理和進行。全球感染疾病和慢性病的流行以及隨之而來的製藥和生物製藥行業的臨床試驗和研發費用的增加將刺激市場成長。與臨床試驗供應相關的高成本、嚴格的供應法規以及跨境物流挑戰限制了市場成長。專注於藥物開發和轉向以患者為中心的臨床試驗可以改善臨床試驗患者招募、試驗入組和參與者保留率。此外,不同主題_KEYWORD的持續進展預計將為製藥和生物製藥公司開闢新的研究途徑。
主要市場統計 | |
---|---|
基準年[2023] | 33.5億美元 |
預測年份 [2024] | 36.4億美元 |
預測年份 [2030] | 59.2億美元 |
複合年成長率(%) | 8.43% |
區域洞察
以美國和加拿大為中心的美洲地區慢性病診斷率高,醫療基礎設施強大,對臨床試驗供應高度依賴。去年註冊的主要專利與最佳化供應鏈模型和採用先進分析來匹配測試供應與需求有關。由於醫療保健的取得和支出存在差異,歐盟 (EU)、中東和非洲的需求多種多樣。在歐洲,受研發密集投資和老年人口快速成長的推動,對 Theme_KEYWORD 的需求穩定。相較之下,中東和非洲國家是新興市場,研究活動活躍,但資金和基礎設施有限。包括中國、日本和印度在內的亞太地區由於醫療基礎設施的大量投資,疾病發生率很高。蓬勃發展的製藥業正在推動這些地區的臨床試驗用品市場,其需求是由成本效益而不是速度驅動的。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在臨床試驗用品市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對臨床試驗用品市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在臨床試驗用品市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[199 Pages Report] The Clinical Trial Supplies Market size was estimated at USD 3.35 billion in 2023 and expected to reach USD 3.64 billion in 2024, at a CAGR 8.43% to reach USD 5.92 billion by 2030.
Clinical trial supplies are a fundamental yet complex component of clinical research, ultimately helping pave the way toward successful therapeutic breakthroughs and monumental enhancements in patient care pathways. These supplies cater to various research phases, from pre-clinical examinations to post-marketing surveillance studies, thus facilitating the seamless management and execution of clinical investigations. The increasing prevalence of infectious and chronic diseases worldwide and the subsequent rise in clinical trials with research and development expenditure of the pharmaceutical and biopharmaceutical industry stimulates market growth. The high cost associated with clinical trial supplies, stringent regulations for supplies, and cross-border logistics challenges restrict market growth. Growing emphasis on drug development and shifting towards patient-centric clinical trials offer the potential for better clinical trial patient recruitment, study enrollment, and participant retention. In addition, ongoing advancements in a diverse range of clinical trial supplies are expected to open new research avenues for pharmaceutical and biopharmaceutical companies.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.35 billion |
Estimated Year [2024] | USD 3.64 billion |
Forecast Year [2030] | USD 5.92 billion |
CAGR (%) | 8.43% |
Regional Insights
In the Americas, primarily the United States and Canada, there is a significant dependence on clinical trial supplies due to a high diagnosis rate of chronic diseases and robust healthcare infrastructure. Over the past year, the major patents registered revolved around optimizing supply chain models and employing advanced analytics to align trial supply with demand. The European Union (EU), the Middle East, and Africa exhibit a diverse range of needs due to discrepancies in healthcare access and spending. Europe witnesses steady demand for clinical trial supplies, fueled by heavy investments in research and development initiatives and a surge in the geriatric population. In contrast, Middle Eastern and African countries encompass emerging markets with rising research activities yet laid back due to limited funding and infrastructural impediments. Asia-Pacific, including China, Japan, and India, reports a high disease prevalence, bridged by substantial investments in improving healthcare infrastructure. The booming pharmaceutical industry drives the clinical trial supplies market in these regions, and the demand is dictated more by cost-efficacy rather than speed, mirroring their unique healthcare economic dynamics.
Market Insights
The market dynamics represent an ever-changing landscape of the Clinical Trial Supplies Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Clinical Trial Supplies Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Clinical Trial Supplies Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Signal: UK Clinical Research Provider Ergomed Bought Out in USD 888 Million Deal
Permira, a UK private equity firm, agreed to acquire Ergomed for USD 888.1 million. Ergomed is a clinical trial development and management services provider, catering to clients across more than 100 countries. This strategic acquisition can expand Permira's already impressive portfolio of medical companies, including Neurapharm and Cambrex. [Published On: 2023-09-04]
Thermo Fisher Scientific Launches New Smart Refrigerator Series
Thermo Fisher Scientific introduced the Thermo Scientific TM TSG series refrigerators, specifically engineered to cater to the stringent demands of diverse industries. These cutting-edge refrigerators leverage advanced technology to ensure accurate temperature control, effectively preserving the integrity of vaccines and pharmaceuticals. By minimizing temperature fluctuations, these refrigerators effectively mitigate the risks associated with such variations, safeguarding medical products' potency and efficacy. [Published On: 2023-08-16]
Loftware and Tenthpin Collaborate on Clinical Supply Labeling
Loftware and Tenthpin collaborated to launch a software called Loftware Prisym 360, which is specifically designed for clinical supply labeling. The main objective of this partnership is to address the growing challenges faced by clinical trial supply teams within the pharmaceutical industry. This agreement enables both Loftware and Tenthpin to actively promote, educate, and implement a comprehensive content and labeling solution for their clinical customers. [Published On: 2023-08-02]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Clinical Trial Supplies Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Clinical Trial Supplies Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Abbott Laboratories, Almac Group Limited, B. Braun SE, Baxter International, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bruker Corporation, Cardinal Health, Inc., Charles River Laboratories, Inc., COREX LOGISTICS LIMITED, Emsere B.V by Medicapital Holdco B.V., Eppendorf SE, Evident Corporation by Olympus Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Group, Hipro Biotechnology Co., Ltd., Hitachi, Ltd., HORIBA, Ltd., ICON PLC, Immudex ApS, Incyte Corporation, IQVIA Inc., Johnson & Johnson Services, Inc., KLIFO A/S, Labnet International, Leica Microsystems GmbH by Danaher Corporation, llumina, Inc., Lonza Group Ltd., Medline Industries, LP, Merck KGaA, Myonex, LLC, Novo Nordisk A/S, Nuvisan GmbH, Parexel International Corporation, Perceptive Informatics LLC and its affiliates, d/b/a Calyx, PerkinElmer Inc. by Revvity, Inc., Pfizer Inc., Promega Corporation, Recipharm AB, Rubicon Research Pvt. Ltd., Sekisui Diagnostics Group, Sharp Services, LLC, Siemens Healthcare GmbH, Smith & Nephew PLC, Stryker Corporation, Thermo Fisher Scientific Inc., and Woodley Equipment Company Ltd..
Market Segmentation & Coverage